AKUMS.NS
Strong BuyPremium GrowerAI neutralAkums Drugs and Pharmaceuticals Limited · Healthcare · India · $1.3B
INR 801.35 -1.4% · close 5 Oct · scored 7 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Akums is India's largest contract developer and manufacturer of formulations for domestic and multinational drug companies, listed since August 2024. Its scale in outsourced manufacturing gives it a cost position that smaller rivals struggle to match, and price momentum is strong. The evidence stops there: there is no recent intelligence on order wins, margin trajectory or pricing, and contract manufacturing for the domestic market has historically carried thin margins and limited pricing power. Valuation is middling for the quality on offer, so the growth-at-a-reasonable-price case is not yet demonstrated.
ABOUT AKUMS DRUGS AND PHARMACEUTICALS LIMITED
Read
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.7B | 40.2B | 40.7B | 42.5B | 7.0% | 45.1B | 49.0B | 56.4B | 15.2% |
| EPS (INR) | 6.03 | -0.28 | 22.60 | 16.67 | 40.4% | 19.05 | 25.87 | — | 55.2% |
| Shares | 153.1M | 153.1M | 153.1M | 153.1M | -0.0% | 153.1M | — | — | — |
| Debt | 6.2B | 5.7B | 882.1M | 1.9B | -32.3% | 1.9B | — | — | — |
| Equity | 7.2B | 7.1B | 30.5B | 33.1B | 66.5% | — | — | — | — |
| Op CF | 1.8B | 5.0B | 4.7B | 11.8B | 88.4% | 12.0B | — | — | — |
| Inv CF | -3.0B | -3.3B | -5.5B | -9.3B | — | — | — | — | — |
| Fin CF | 1.2B | -1.1B | 727.9M | 338.8M | — | — | — | — | — |
Calmer than 66% of stocks we rank over the past year (33% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AKUMS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited(you) | $1.3B | 95 | Strong Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 91 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $937M | 92 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 90 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.1B | 85 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 85 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $690M | 89 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $622M | 90 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $761M | 86 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.3B | 86 | Strong Buy |
Peer medians: ROE 11.9% · P/E 43.0x · Gross margin 59.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.